{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T22:43:18Z","timestamp":1770417798336,"version":"3.49.0"},"reference-count":32,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,1,19]],"date-time":"2022-01-19T00:00:00Z","timestamp":1642550400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Interleukin-6 (IL-6), a pleiotropic cytokine that regulates immune responses and inflammatory reactions, plays a pivotal role in the development of rheumatoid arthritis (RA). Blockade of IL-6 signaling with the monoclonal antibody (mAb) represents an important advancement in RA treatment. Although two IL-6 receptor antibodies are already available in the clinic, there is no mAb specifically targeting the human IL-6 to block IL-6 signaling for RA treatment. In this study, we have developed a novel humanized anti-IL-6 mAb HZ-0408b with potent binding and neutralizing activity to human IL-6. We demonstrated that HZ-0408b has a high species specificity and low cross-reactivity. Moreover, HZ-0408b showed a more potent inhibitory effect on IL-6 signaling than Siltuximab, an FDA-approved anti-IL-6 chimeric mAb. HZ-0408b is comparable to Olokizumab, a humanized mAb against IL-6 that is already in phase III studies. We observed that HZ-0408b is well tolerated at doses that can achieve therapeutic serum levels in cynomolgus monkey. Most importantly, we proved that HZ-0408b treatment significantly ameliorated joint swelling after the onset of arthritis and dramatically reduced plasma C-reactive protein (CRP) levels in a monkey collagen-induced arthritis (CIA) model. Collectively, our findings using non-human primates indicate that humanized anti-IL-6 mAb HZ-0408b has excellent safety and efficacy profiles for RA therapy.<\/jats:p>","DOI":"10.3389\/fimmu.2021.816646","type":"journal-article","created":{"date-parts":[[2022,1,19]],"date-time":"2022-01-19T11:17:12Z","timestamp":1642591032000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":11,"title":["A Novel Humanized Anti-Interleukin-6 Antibody HZ0408b With Anti-Rheumatoid Arthritis Therapeutic Potential"],"prefix":"10.3389","volume":"12","author":[{"given":"Xiaolei","family":"Liu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qian","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fengchao","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fei","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongjun","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jian","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2022,1,19]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"a016295","DOI":"10.1101\/cshperspect.a016295","article-title":"IL-6 in Inflammation, Immunity, and Disease","volume":"6","author":"Tanaka","year":"2014","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1038\/nrd.2018.45","article-title":"Interleukin-6: Designing Specific Therapeutics for a Complex Cytokine","volume":"17","author":"Garbers","year":"2018","journal-title":"Nat Rev Drug Discov"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1038\/324073a0","article-title":"Complementary DNA for a Novel Human Interleukin (BSF-2) That Induces B Lymphocytes to Produce Immunoglobulin","volume":"324","author":"Hirano","year":"1986","journal-title":"Nature"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1126\/science.3136546","article-title":"Cloning and Expression of the Human Interleukin-6 (BSF-2\/IFN Beta 2) Receptor","volume":"241","author":"Yamasaki","year":"1988","journal-title":"Science"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1126\/science.8197455","article-title":"Jak-STAT Pathways and Transcriptional Activation in Response to IFNs and Other Extracellular Signaling Proteins","volume":"264","author":"Darnell","year":"1994","journal-title":"Science"},{"key":"B6","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1007\/s40744-020-00219-2","article-title":"Understanding the Role of Interleukin-6 (IL-6) in the Joint and Beyond: A Comprehensive Review of IL-6 Inhibition for the Management of Rheumatoid Arthritis","volume":"7","author":"Favalli","year":"2020","journal-title":"Rheumatol Ther"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1097\/BOR.0000000000000267","article-title":"Comorbidities in Rheumatoid Arthritis","volume":"28","author":"Dougados","year":"2016","journal-title":"Curr Opin Rheumatol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"R204","DOI":"10.1186\/ar4397","article-title":"Effect of Tocilizumab on Haematological Markers Implicates Interleukin-6 Signalling in the Anaemia of Rheumatoid Arthritis","volume":"15","author":"Isaacs","year":"2013","journal-title":"Arthritis Res Ther"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1002\/art.39093","article-title":"Sarilumab Plus Methotrexate in Patients With Active Rheumatoid Arthritis and Inadequate Response to Methotrexate: Results of a Phase III Study","volume":"67","author":"Genovese","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.4161\/mabs.1.5.9497","article-title":"Tocilizumab","volume":"1","author":"Venkiteshwaran","year":"2009","journal-title":"MAbs"},{"key":"B11","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s40744-018-0102-x","article-title":"A Review of Recent Advances Using Tocilizumab in the Treatment of Rheumatic Diseases","volume":"5","author":"Rubbert-Roth","year":"2018","journal-title":"Rheumatol Ther"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-204760","article-title":"Efficacy and Safety of Olokizumab in Patients With Rheumatoid Arthritis With an Inadequate Response to TNF Inhibitor Therapy: Outcomes of a Randomised Phase IIb Study","volume":"73","author":"Genovese","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1038\/321522a0","article-title":"Replacing the Complementarity-Determining Regions in a Human Antibody With Those From a Mouse","volume":"321","author":"Jones","year":"1986","journal-title":"Nature"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.2741\/2786","article-title":"Humanization of Antibodies","volume":"13","author":"Almagro","year":"2008","journal-title":"Front Biosci"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/0161-5890(94)90115-5","article-title":"Reshaping a Human Antibody to Inhibit the Interleukin 6-Dependent Tumor Cell Growth","volume":"53","author":"Sato","year":"1993","journal-title":"Cancer Res"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1006\/clim.2000.4989","article-title":"Humanized Antibody to Human Interleukin-6 Receptor Inhibits the Development of Collagen Arthritis in Cynomolgus Monkeys","volume":"98","author":"Mihara","year":"2001","journal-title":"Clin Immunol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1248\/bpb.31.1159","article-title":"Tocilizumab, a Humanized Anti-Interleukin-6 Receptor Antibody, Ameliorates Joint Swelling in Established Monkey Collagen-Induced Arthritis","volume":"31","author":"Uchiyama","year":"2008","journal-title":"Biol Pharm Bull"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1007\/s11912-002-0023-1","article-title":"The Role of C-Reactive Protein as a Prognostic Indicator in Advanced Cancer","volume":"4","author":"Mahmoud","year":"2002","journal-title":"Curr Oncol Rep"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-210310","article-title":"Efficacy and Safety of Sarilumab Monotherapy Versus Adalimumab Monotherapy for the Treatment of Patients With Active Rheumatoid Arthritis (MONARCH): A Randomised, Double-Blind, Parallel-Group Phase III Trial","volume":"76","author":"Burmester","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)70319-5","article-title":"Siltuximab for Multicentric Castleman\u2019s Disease: A Randomised, Double-Blind, Placebo-Controlled Trial","volume":"15","author":"van Rhee","year":"2014","journal-title":"Lancet Oncol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1038\/s41573-020-0078-4","article-title":"Soluble Ligands as Drug Targets","volume":"19","author":"Attwood","year":"2020","journal-title":"Nat Rev Drug Discov"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/0090-1229(89)90146-3","article-title":"Interleukin-6 in Synovial Fluid From Patients With Arthritis","volume":"50","author":"Waage","year":"1989","journal-title":"Clin Immunol Immunopathol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19910415)67:8<2087::AID-CNCR2820670814>3.0.CO;2-R","article-title":"Bladder Cancer. Human Leukocyte Antigen II, Interleukin-6, and Interleukin-6 Receptor Expression Determined by the Polymerase Chain Reaction","volume":"67","author":"Meyers","year":"1991","journal-title":"Cancer"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1002\/eji.1830221110","article-title":"High Amounts of Circulating Interleukin (IL)-6 in the Form of Monomeric Immune Complexes During Anti-IL-6 Therapy. Towards a New Methodology for Measuring Overall Cytokine Production in Human In Vivo","volume":"22","author":"Lu","year":"1992","journal-title":"Eur J Immunol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/S1043-4666(05)80007-9","article-title":"Overall Interleukin-6 Production Exceeds 7 Mg\/Day in Multiple Myeloma Complicated by Sepsis","volume":"5","author":"Lu","year":"1993","journal-title":"Cytokine"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V86.8.3123.3123","article-title":"Measurement of Whole Body Interleukin-6 (IL-6) Production: Prediction of the Efficacy of Anti-IL-6 Treatments","volume":"86","author":"Lu","year":"1995","journal-title":"Blood"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1080\/09629359890875","article-title":"Serum Levels of Interleukin-6 Type Cytokines and Soluble Interleukin-6 Receptor in Patients With Rheumatoid Arthritis","volume":"7","author":"Robak","year":"1998","journal-title":"Mediators Inflamm"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-020-0419-z","article-title":"Translating IL-6 Biology Into Effective Treatments","volume":"16","author":"Choy","year":"2020","journal-title":"Nat Rev Rheumatol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1002\/art.20303","article-title":"Treatment of Rheumatoid Arthritis With Humanized Anti-Interleukin-6 Receptor Antibody: A Multicenter, Double-Blind, Placebo-Controlled Trial","volume":"50","author":"Nishimoto","year":"2004","journal-title":"Arthritis Rheum"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-210297","article-title":"Low Immunogenicity of Tocilizumab in Patients With Rheumatoid Arthritis","volume":"76","author":"Burmester","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(20)30404-5","article-title":"Cytokine Elevation in Severe and Critical COVID-19: A Rapid Systematic Review, Meta-Analysis, and Comparison With Other Inflammatory Syndromes","volume":"8","author":"Leisman","year":"2020","journal-title":"Lancet Respir Med"},{"key":"B32","doi-asserted-by":"publisher","first-page":"e13","DOI":"10.1016\/S2213-2600(20)30600-7","article-title":"Assessing the Importance of Interleukin-6 in COVID-19","volume":"9","author":"Chen","year":"2021","journal-title":"Lancet Respir Med"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2021.816646\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,19]],"date-time":"2022-01-19T11:17:15Z","timestamp":1642591035000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2021.816646\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,19]]},"references-count":32,"alternative-id":["10.3389\/fimmu.2021.816646"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2021.816646","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,19]]},"article-number":"816646"}}